The company has also entered into a financial advisory agreement with EastGate Financial to provide consulting and advisory services with respect to establishing an office in New York, advise the company in applying for listing on the American Stock Exchange (Amex) and assist in identifying and choosing an Amex specialist firm. The agreement with EastGate is in coordination with and complementary to Benda’s strategic relationship with CRT.
Yiqing Wan, Benda’s chairman and CEO, said: “Entering into these new strategic relationships with CRT and EastGate is a watershed moment in our development into a leading pharmaceutical company, both in China and beyond. CRT and EastGate both have deep experience in our space, and CRT’s demonstrated success in helping evolve one of our closest peer companies, American Oriental Bioengineering, gives us the utmost confidence that the relationship will help us achieve each of our operational and financial goals.”